New advances in the treatment of atrial fibrillation: focus on stroke prevention

Bibliography

• Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005;36(6):1115-19
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33(21):2719-47
   PubMed Web of Science ®Google Scholar
• Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013;34(35):2746-51
   PubMed Web of Science ®Google Scholar
• Grond M, Jauss M, Hamann G, et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke 2013;44(12):3357-64
   PubMed Web of Science ®Google Scholar
• Sadowski JA, Suttie JW. Mechanism of action of coumarins. Significance of vitamin K epoxide. Biochemistry 1974;13(18):3696-9
   PubMedGoogle Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146(12):857-67
   PubMed Web of Science ®Google Scholar
• Schulman S, Beyth RJ, Kearon C, et al. American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):257S-98S
   PubMed Web of Science ®Google Scholar
• Sotaniemi EA, Arranto AJ, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997;61(3):331-9
   PubMed Web of Science ®Google Scholar
• Moyer TP, O’Kane DJ, Baudhuin LM, et al. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc 2009;84(12):1079-94
   PubMed Web of Science ®Google Scholar
• Carlquist JF, Horne BD, Muhlestein JB, et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 2006;22(3):191-7
   PubMed Web of Science ®Google Scholar
• De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis–Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;110(6):1087-107
   PubMed Web of Science ®Google Scholar
• Gallego P, Roldan V, Marin F, et al. SAME-TTR score, time in therapeutic range and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 2014. [ Epub ahead of print]
   PubMedGoogle Scholar
• Gallego P, Roldan V, Marin F, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013;110(6):1189-98
   PubMed Web of Science ®Google Scholar
• Gallagher AM, Setakis E, Plumb JM, et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011;106(5):968-77
   PubMed Web of Science ®Google Scholar
• Van Den Ham HA, Klungel OH, Leufkens HG, et al. The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation. J Thromb Haemost 2013;11(1):107-15
   PubMed Web of Science ®Google Scholar
• Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8(9):651-745
   PubMedGoogle Scholar
• McBridge R. Stroke Prevention in atrial fibrillation study. Final results. Circulation 1991;84:527-39
   PubMedGoogle Scholar
• Chesebro JH, Wiebers DO, Holland AE, et al. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke prevention in atrial fibrillation II study. Lancet 1994;343:687-91
   PubMedGoogle Scholar
• Stroke Prevention in Atrial Fibrillation investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348(9028):633-8
   PubMed Web of Science ®Google Scholar
• Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370(9586):493-503
   PubMed Web of Science ®Google Scholar
• Investigators A, Connolly SJ, Pogue J, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360(20):2066-78
   PubMedGoogle Scholar
• De Caterina R, Husted S, Wallentin L, et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis–Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;109(4):569-79
   PubMed Web of Science ®Google Scholar
• Husted S, De Caterina R, Andreotti F, et al. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. Thromb Haemost 2014;111(5):781-2
   PubMed Web of Science ®Google Scholar
• Pisters R, Nieuwlaat R, Lane DA, et al. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. Thromb Haemost 2013;109(2):328-36
   PubMed Web of Science ®Google Scholar
• Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15(5):625-51
   PubMed Web of Science ®Google Scholar
• Potpara TS, Lip GY. Novel oral anticoagulants in non-valvular atrial fibrillation. Best Pract Res Clin Haematol 2013;26(2):115-29
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981-92
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369(22):2093-104
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364(9):806-17
   PubMed Web of Science ®Google Scholar
• Diener HC, Eikelboom J, Connolly SJ, et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol 2012;11(3):225-31
   PubMed Web of Science ®Google Scholar
• Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36(2):386-99
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64(3):292-303
   PubMed Web of Science ®Google Scholar
• Huisman MV, Lip GY, Diener HC, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012;107(5):838-47
   PubMed Web of Science ®Google Scholar
• Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013;368(14):1272-4
   PubMed Web of Science ®Google Scholar
• Larsen TB, Rasmussen LH, Skjoth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013;61(22):2264-73
   PubMed Web of Science ®Google Scholar
• Banerjee A, Lane DA, Torp-Pedersen C, et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ’real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012;107(3):584-9
   PubMed Web of Science ®Google Scholar
• Bansal N, Hsu CY, Go AS. Intersection of cardiovascular disease and kidney disease: atrial fibrillation. Curr Opin Nephrol Hypertens 2014;23(3):275-82
   PubMedGoogle Scholar
• Bansal N, Fan D, Hsu CY, et al. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation 2013;127(5):569-74
   PubMed Web of Science ®Google Scholar
• Guo Y, Wang H, Zhao X, et al. Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. Int J Cardiol 2013;168(5):4678-84
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012;33(22):2821-30
   PubMed Web of Science ®Google Scholar
• Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 2014;111(5):789-97
   PubMedGoogle Scholar
• Wang D, Chen H, Momary KM, et al. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 2008;112(4):1013-21
   PubMed Web of Science ®Google Scholar
• Park SM, Lee JK, Chun SI, et al. VKORC1 and CYP2C9 genotype variations in relation to warfarin dosing in Korean stroke patients. J Stroke 2013;15(2):115-21
   PubMedGoogle Scholar
• Miyagata Y, Nakai K, Sugiyama Y. Clinical significance of combined CYP2C9 and VKORC1 genotypes in Japanese patients requiring warfarin. Int Heart J 2011;52(1):44-9
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369(13):1206-14
   PubMed Web of Science ®Google Scholar
• Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost 2010;103(1):13-28
   PubMedGoogle Scholar
• Bernard A, Fauchier L, Pellegrin C, et al. Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation. Thromb Haemost 2013;110(3):560-8
   PubMed Web of Science ®Google Scholar
• Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381(9872):1107-15
   PubMed Web of Science ®Google Scholar
• Lamberts M, Gislason GH, Lip GY, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 2014;129(15):1577-85
   PubMed Web of Science ®Google Scholar
• Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012;107(5):985-97
   PubMed Web of Science ®Google Scholar
• Hillarp A, Gustafsson KM, Faxalv L, et al. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-Xa assays. J Thromb Haemost 2014. [ Epub ahead of print]
   PubMedGoogle Scholar
• Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138(5):1093-100
   PubMed Web of Science ®Google Scholar
• Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013;34(27):2094-106
   PubMed Web of Science ®Google Scholar
• Lowe MP, Collins J, Yehia M, et al. Reversal of dabigatran with haemodialysis in a patient requiring decompression for cord compression from an epidural abscess. Nephrology (Carlton) 2013;18(8):580-2
   PubMed Web of Science ®Google Scholar
• Chen BC, Sheth NR, Dadzie KA, et al. Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose. Am J Kidney Dis 2013;62(3):591-4
   PubMed Web of Science ®Google Scholar
• Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis 2013;61(3):487-9
   PubMed Web of Science ®Google Scholar
• Pernod G, Albaladejo P, Godier A, et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis 2013;106(6-7):382-93
   PubMed Web of Science ®Google Scholar
• Fatkin D, Feneley M. Stratification of thromboembolic risk of atrial fibrillation by transthoracic echocardiography and transesophageal echocardiography: the relative role of left atrial appendage function, mitral valve disease, and spontaneous echocardiographic contrast. Prog Cardiovasc Dis 1996;39(1):57-68
   PubMedGoogle Scholar
• Fatkin D, Kelly R, Feneley MP. Left atrial appendage blood velocity and thromboembolic risk in patients with atrial fibrillation. J Am Coll Cardiol 1994;24(5):1429-30
   PubMedGoogle Scholar
• Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation 2013;127(6):720-9
   PubMed Web of Science ®Google Scholar
• Amorosi SL, Armstrong S, Da Deppo L, et al. The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation. Europace 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Reddy VY, Mobius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol 2013;61(25):2551-6
   PubMed Web of Science ®Google Scholar
• Stambler BS. A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin. Int Arch Med 2013;6(1):46
   PubMedGoogle Scholar